TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06063083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell Me More (Dime Mas)
Description: Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Ambassador Stories [Listen Miami (Oye Miami)]
Description: Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Ambassador Stories [Listen Miami (Oye Miami)]
Description: Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Community Outreach
Description: Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Outreach
Description: Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Community Outreach
Description: Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
Study: NCT06456762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPEACE: Intervention for Parent Education about Care after the ED
Description: Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging Reminders Only
Description: Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
Study: NCT06360627

Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomography
Description: Computed Tomography CHEST

Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomography
Description: Computed Tomography CHEST
Study: NCT03657056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BX Pulsar 1002
Description: LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz).
Study: NCT05742555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Description: After the relatives of the patients included in the experimental group are informed about the study, they will be asked to fill in the Participant Information Form, Nottingham Health Profile (NSP) and Warwick-Edinburgh Mental Well-Being Scale (WEMIOÖ) after obtaining their permission. The virtual reality intervention will be applied to the caregivers at a suitable time of the day (when the patient's care and treatment is not intensive, the caregiver wishes). Different nature scenes (sea, forest, stream) with different types of music (classical music, nature sounds, relaxing music) will be watched for 10 minutes, 3 days a week. The application will be made for 4 weeks. At the end of this period, they will be asked to fill the NSP and WEMİOÖ again as a final test.
Study: NCT06019442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (Health4Her-Automated)
Description: Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle health promotion
Description: Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle health promotion
Description: Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight).
Study: NCT04737200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Time-of-day of enteral nutrition provision (daytime first)
Description: Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Time-of-day of enteral nutrition provision (nighttime first)
Description: Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
Study: NCT05739084

Intervention type: RADIATION
Intervention: pre-operative radiation
Description: As per standard of care and institutional guidelines

Intervention type: RADIATION
Intervention: pre-operative radiation
Description: As per standard of care and institutional guidelines

Intervention type: PROCEDURE
Intervention: Standard surgery after rpreoprative radiation
Description: As per standard of care and institutional guidelines

Intervention type: PROCEDURE
Intervention: Standard surgery after rpreoprative radiation
Description: As per standard of care and institutional guidelines
Study: NCT05083637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L- carnitine oral solution
Description: The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
Study: NCT04800731

Intervention type: OTHER
Intervention: observation no intervention
Description: no intervention

Intervention type: OTHER
Intervention: observation no intervention
Description: no intervention

Intervention type: OTHER
Intervention: observation no intervention
Description: no intervention
Study: NCT06318702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
Study: NCT04810377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy
Description: First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
Study: NCT05964777

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation
Description: with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation
Description: with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation
Description: with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.
Study: NCT06325332

Intervention type: OTHER
Intervention: Nirsevimab
Description: Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
Study: NCT04770909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for dietary self-monitoring and weight loss
Description: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for dietary self-monitoring
Description: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for weight loss
Description: Participants can earn up to $300 during the trial for achieving weight loss
Study: NCT05180097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV, 30 mins D1, D8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg daily PO, D1-D4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2 IV, 1 hour, D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg IV, 30 mins, Q21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200mg IV, 30 mins, Q 21 days
Study: NCT05376579

Intervention type: OTHER
Intervention: siponimod
Description: Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
Study: NCT06492330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS0159
Description: The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS0159 placebo
Description: The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
Study: NCT06459180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Tirumotecan
Description: IV infusion
Study: NCT05617287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semaine Menopause Supplement
Description: Synergistic Dietary Supplement
Study: NCT06460740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Cycling
Description: In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
Study: NCT06523829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP GIVEN VIDEO TRAINING
Description: Video-based training was given to this group.
Study: NCT06459180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tisotumab Vedotin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV infusion
Study: NCT06639503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 5mL 0.25% bupivacain
Study: NCT03909594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine
Study: NCT00012597

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Web-based telemedicine system for assessment of status of pressure ulcers
Study: NCT06365970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
Study: NCT05090332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Gun
Description: Vibration massage applied for five Minutes directly on the trigger point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Gun
Description: Vibration massage applied for five Minutes directly on the trigger point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
Study: NCT06496542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily caloric restriction
Description: Weight loss based on daily caloric restriction and increased physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Standard advice control
Description: Initial nutrition consultation without subsequent counseling
Study: NCT04978766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Book Reading
Description: The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification.
Study: NCT05687630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic band resisted exercise
Description: muscle strengthening exercise, 10-15 times of each set, for 3 sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic band resisted exercise
Description: muscle strengthening exercise, 10-15 times of each set, for 3 sets
Study: NCT04926818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod placebo
Description: Fingolimod matching placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Siponimod placebo
Description: Siponimod matching placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ofatumumab placebo
Description: Ofatumumab matching placebo autoinjector
Study: NCT05541614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative
Description: Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain® - Enamel Matrix Derivative
Description: Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.